Eosinophilic Esophagitis - A Pipeline Analysis Report
- Published: Mar 2018
- Pages: 67
- SKU: IRTNTR21484
The 2022-2026 version of this report is just being published. Buy it now and get up to $1000 worth of free customization!
This pipeline analysis report provides detailed insights into the drug development landscape of the drug development for eosinophilic esophagitis including molecules at pre-clinical, pre-registration, and various other developmental stages. The report also offers comprehensive information about the drug development strategies of the pipeline molecules based on various segmentations such as therapies employed, route of administration, therapeutic modalities, and targets for the drugs under development.
Overview of the drug development for eosinophilic esophagitis
Eosinophilic esophagitis is a chronic immune-mediated disorder of the esophagus that affects individuals of all age groups including both adults and children. This disorder is also known as asthma of the esophagus. Patients suffering from this condition are diagnosed with a large number of white blood cells in the tissues of the esophagus. These white blood cells are known as eosinophils. Factors such as the damage to the esophagus, multiplication of eosinophils, and reaction of the esophagus can result in eosinophilic esophagitis disorder. Technavio’s market research analysts have predicted that with the introduction of dietary therapy, proton pump inhibitor (PPI), and topical steroid as some of the most promising investigational approaches to treat eosinophilic esophagitis, the eosinophilic esophagitis market size, and share will increase in the forthcoming years.
According to this pipeline analysis report, most of the drug development molecules in the pipeline are under the pre-clinical drug development stage. Our market research analysts have also identified that almost the same amount of drug molecules comes under the phase II drug development stage. The pipeline landscape in the pipeline analysis report mentions the percentage of drug development molecules that are under the pre-registration and phase III stage.
This pipeline analysis report mentions the eosinophilic esophagitis market opportunity and provides a detailed analysis of the companies that are involved in the development of drug molecules for the treatment of eosinophilic esophagitis. In addition to providing information on the various stages of molecules developed by companies for different drug development landscape, this pipeline analysis report also provides information about the drug development molecules discontinued by companies.
Some of the companies covered in this pipeline analysis report are –
- Adare Pharmaceuticals
- Biotica Pharmaceuticals
- Calypso Biotech
Drug development strategies of the drug development for eosinophilic esophagitis by route of administration
- Intravenous and subcutaneous
The oral route of administration (ROA) involves the administration of drugs through a mouth cavity. It has been observed that the majority of total therapeutics are being developed for oral administration.
Drug development strategies of the drug development for eosinophilic esophagitis for therapeutic modalities
- Monoclonal antibodies
- Small molecules
According to this pipeline analysis report, some of the molecules that are currently in the drug development pipeline for eosinophilic esophagitis are being developed as monoclonal antibodies. Monoclonal antibodies bind to only one substance in the body as they are made by identical immune cells that are all clones of a unique parent cell.
Key questions answered in the report include
- What are the drug development molecules in the various development stages for eosinophilic esophagitis?
- What are the companies that are currently involved in the development of drug development molecules for eosinophilic esophagitis?
- Insight into discontinued/inactive molecules with appropriate reasoning?
- What are the major regulatory authorities approving drugs in various regions?
- Detailed profiling of each active molecule
Technavio also offers customization on reports based on specific client requirement.
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: INTRODUCTION
PART 05: MAJOR REGULATORY AUTHORITIES
PART 06: PIPELINE LANDSCAPE
PART 07: COMPARATIVE ANALYSIS
- Discovery stage molecules
- Pre-clinical stage molecules
- Inactive and discontinued molecules
PART 08: INDICATION ANALYSIS
PART 09: THERAPEUTIC ASSESSMENT (THERAPY BASED)
PART 10: THERAPEUTIC ASSESSMENT (ROA BASED)
PART 11: THERAPEUTIC ASSESSMENT BY TARGET
PART 12: KEY COMPANIES
- Active companies: Category and parameters
PART 13: APPENDIX
- List of abbreviations
Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.
- Market size and forecast
- Market segmentation
- Geographical insights
- Competitive landscape
Get your FREE sample now!
Get the report (PDF) sent to your email within minutes.
Subscribe & Save
Get lifetime access to our
Did you know?
Did you know?
Did you know?
Want to customize this report?
This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time.